Search Results
Your search for ,are matches 22257 pages
Showing 19901 - 19950Colorectal Liver Metastases: Thumbs Up for Radiofrequency Ablation, Jury Still Out for Selective Internal Radiotherapy
Two “firsts” in studies of colorectal liver metastases were highlighted at the 2015 ASCO Annual Meeting: the first prospective randomized trial to evaluate radiofrequency ablation plus chemotherapy1 and the first large randomized phase III trial to study liver-directed selective internal radiation...
Indolent Lymphoma: A More Complex Malignancy Than Once Thought
With a growing number of options for follicular lymphoma, clinicians may wonder whether there is one best regimen. James O. Armitage, MD, FACP, FRCP, Professor of Medicine at the University of Nebraska, Omaha—and Editor-in-Chief of The ASCO Post—tackled this question and offered recommendations at...
Positioning Targeted and Immunotherapy-Based Approaches in Lung Cancer
With immunotherapy changing the face of lung cancer, is there still a place for targeted therapy? Two experts from Emory University debated this issue at the 2015 Debates and Didactics in Hematology and Oncology Conference held in Sea Island, Georgia. Fadlo Khuri, MD, was recently named President...
Charting a New Course: From Clinical Investigator to University President
What first intrigued Fadlo R. Khuri, MD, FACP, about the prospect of becoming the 16th President of the American University of Beirut (AUB) in Lebanon was the chance to give back to an institution and a country that had given him so much. Born in Boston, Massachusetts, in 1963, Dr. Khuri was raised ...
Our Patients Are the True Heroes of Cancer Research
A few weeks ago, I read an op-ed1 in The New York Times written by Stan Collender, a patient with Merkel cell carcinoma, a rare and aggressive type of skin cancer. In his article, he described his participation in a clinical trial for a new drug he is hoping will stem progression of his cancer and...
Elotuzumab Ushers in a New Era in Myeloma Therapy
The long wait for monoclonal antibodies for the treatment of multiple myeloma is over. In the landmark ELOQUENT-2 study, reviewed in this issue of The ASCO Post, Lonial and colleagues convincingly demonstrate the effectiveness of elotuzumab, a monoclonal antibody directed against SLAMF7, in the...
Azacitidine Increased Median Overall Survival Among Patients Aged 65 and Older With > 30% Blasts
A multicenter, randomized, open-label, phase III trial among the difficult-to-treat population of patients aged aged 65 and older with acute myeloid leukemia (AML) with > 30% bone marrow blasts “showed that azacitidine was associated with a clinically meaningful improvement” in median overall...
‘Encouraging Results’ With Newer EGFR TKIs in Patients With NSCLC Who Progressed After Prior EGFR TKI Therapy
Two studies of third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors among patients with non–small cell lung cancer (NSCLC) who had progressive disease following treatment with a first-generation EGFR tyrosine kinase inhibitor “show encouraging results,” according to...
My Positive Attitude Is Keeping Me Alive
Until I was diagnosed with stage III renal cell carcinoma in early 2008, I had no firsthand experience with cancer. To my knowledge, there is no history of cancer in my immediate family, and despite a smoking habit I picked up when I was young, I had been in relatively good health in the 56 years...
Let It Be Hard
The ASCO Post is pleased to reproduce installments of the “Art of Oncology” as published previously in the Journal of Clinical Oncology (JCO). These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Internationally Acclaimed Cancer Researcher, Gianni Bonadonna, MD, Dies at 81
Gianni Bonadonna, MD, was considered the “Father of Italian Oncology,” but his scientific contributions to the field and his generous collegial spirit extended far beyond the shores of his native land. Dr. Bonadonna was at the forefront in the battle to convince the surgical establishment that...
ASCO Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility
As reported in the Journal of Clinical Oncology by Mark E. Robson, MD, of Memorial Sloan Kettering Cancer Center, and colleagues, ASCO has issued a policy statement update on genetic and genomic testing for cancer susceptibility.1 The statement, commissioned by ASCO’s Cancer Prevention and Ethics...
In Search of a Good Ending for a Life Well Lived
BOOKMARK Title: The Conversation: A Revolutionary Plan for End-of-life CareAuthor: Angelo E. Volandes, MDPublisher: BloomsburyPublication date: January 13, 2015Price: $26.00; hardcover, 240 pages A quick Google search on books about end-of-life care will yield pages of hits on the subject. The...
An Unvarnished, Behind-the-Scenes Look at the Hospital Nurse
BOOKMARK Title: The Nurses: A Year of Secrets, Drama, and Miracles With the Heroes of the HospitalAuthor: Alexandra RobbinsPublisher: Workman Publishing CompanyPublication date: April 14, 20155Price: $17.53; hardcover, 368 pages Florence Nightingale, the most famous and influential figure in...
Microbes by the Trillions
BOOKMARK Title: 10% Human: How Your Body’s Microbes Hold the Key to Health and HappinessAuthor: Alanna CollenPublisher: Harper CollinsPublication date: April 27, 2015Price: $39.99; hardcover, 400 pages "As I walked back through the forest that night in the summer of 2005, with twenty bats in...
Why It Is Important to Have a Physiatrist on a Cancer Care Team
Physical medicine and rehabilitation in oncology care explores the benefits of cancer rehabilitation in oncology clinical practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. According to a ...
ASCO 2015: Geriatric Oncology Highlights
The theme of the 2015 ASCO Annual Meeting, Illumination and Innovation, is especially appropriate as we consider the field of geriatric oncology. For too long, the elderly cancer patient has remained in the dark regarding treatment planning, clinical trial enrollment, and shared decision-making....
Updated Analysis of Menopausal Hormone Therapy and Breast Cancer Risk
As reviewed in this issue of The ASCO Post, Chlebowski and colleagues1 reported differing patterns of breast cancer risk during or after hormonal therapy with estrogen plus progestin2 or estrogen alone,3 in an analysis of two Women’s Health Initiative (WHI) trials. This recent update on risk...
Immune Checkpoint Inhibitor Nivolumab Is Active in Patients With Heavily Pretreated Advanced Non–Small Cell Lung Cancer
In a phase I cohort expansion trial reported in the Journal of Clinical Oncology, Scott N. Gettinger, MD, of Yale Cancer Center, New Haven, Connecticut, and colleagues found that monotherapy with the anti–programmed cell death protein 1 (PD-1) checkpoint inhibitor antibody nivolumab (Opdivo)...
FDA Grants Regular Approval to Brentuximab Vedotin in High-Risk Classical Hodgkin Lymphoma
The U.S. Food and Drug Administration has approved brentuximab vedotin (Adcetris) as post–autologous hematopoietic stem cell transplantation consolidation treatment for patients with classical Hodgkin lymphoma at high risk of relapse or progression, Seattle Genetics has announced. The approval is...
Food Safety for Patients With Cancer
Cancer.Net and the United States Department of Agriculture’s Food Safety and Inspection Service have collaborated on an infographic of food safety tips for people with cancer. This infographic is an excellent way to help your patients understand which foods are safe to eat, which foods to avoid,...
ASCO Urges Expansion of Cancer Research to Include Older Adults
ASCO issued landmark recommendations in the Journal of Clinical Oncology calling for federal agencies and the cancer research community to broaden clinical trials to include older adults (age 65 and older) and to redefine trial eligibility. More than 60% of cancers in the United States occur in...
Be a Voice in The Campaign to Conquer Cancer
We’ll provide the resources. You provide the voice. The Campaign to Conquer Cancer is raising $150 million to support a world free from the fear of cancer. Our potential to raise money increases with every new person who learns about our work. We need the most trusted leaders in the oncology...
Conquer Cancer Foundation Donor Spotlight: Fibrolamellar Cancer Foundation
When Tucker Davis was diagnosed with fibrolamellar hepatocellular carcinoma (FL-HCC) in 2008, there was very little information about this very rare cancer and, as Tucker would soon discover, even fewer treatment options available. An annoying cough and sharp pain radiating down his back leg...
ASCO University® Releases 2015 Curricula for Advanced Practice Providers (ACAPP™)
ASCO University has released an updated version of ASCO’s Curricula for Advanced Practice Providers (ACAPP™). This popular series assists with the orientation of advanced practice providers (APPs) into oncology practices—a growing need as increasing numbers of APPs are hired to meet the demand for...
Lurie Cancer Center Receives $11.7 Million NCI Grant to Improve Treatment Using Nanotechnology
Northwestern University has received a 5-year, $11.7 million grant from the National Cancer Institute (NCI) to use nanotechnology to develop next-generation cancer treatments. With NCI support, the new Northwestern University Center for Cancer Nanotechnology Excellence (Northwestern CCNE) will use...
FDA Approves Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting
The U.S. Food and Drug Administration (FDA) approved rolapitant (Varubi) to prevent delayed-phase chemotherapy-induced nausea and vomiting. Rolapitant is approved in adults in combination with other antiemetic agents that prevent nausea and vomiting associated with initial and repeat courses of...
ASTRO Awards Seven Physician-Researchers $675,000 in Grants for Radiation Oncology Research
The American Society for Radiation Oncology (ASTRO) has selected seven leading physician-researchers to receive a total of $675,000 in awards and grants to advance radiation oncology research. Together, the grants will support studies in cancer biology, radiation physics, translational research,...
2015 ASTRO Gold Medal Recipients Announced
The American Society for Radiation Oncology (ASTRO) has chosen three radiation oncology physicians and researchers to receive the 2015 ASTRO Gold Medal: Carl R. Bogardus, Jr, MD, FASTRO; Carl M. Mansfield, MD, ScD (Hon), FASTRO; and James B. Mitchell, PhD, FASTRO. Drs. Bogardus, Mansfield, and...
One Doctor’s Road to Palliative Care Services in the Inner City
St. Barnabas Hospital is located in the heart of Bronx, New York, and as such, it has a culturally diverse, largely poor, patient population. The backbone of successful palliative care services is the doctor-patient communication bonding process. However, many of the patients with late-stage cancer ...
Bevacizumab Plus Standard Chemotherapy Improves Survival in Mesothelioma
The standard of care for malignant pleural mesothelioma may be poised for change, judging by results from a study by the French Cooperative Thoracic Intergroup. The addition of bevacizumab (Avastin) in the first-line setting to the current standard of care, pemetrexed (Alimta)/cisplatin, improved...
For Big Data Projects, Bigger Is Better
In an interview with The ASCO Post, Robert S. Miller, MD, FACP, Senior Director, Quality and Guidelines, ASCO, and Medical Director, CancerLinQ™, described how the system could work with data specific to radiation oncology. “The system is in the rapid build phase now, what we are calling the...
Radiation Oncology Looks to Collaboration for Big Data Systems
Radiation oncologists dream of a day when, faced with a new patient sitting in their office, they can quickly consult a computer database offering specific treatment recommendations based on accurate, freshly updated data from millions of previously treated patients with cancer. To hasten that day, ...
Managing High-Risk Patients With Febrile Neutropenia
Febrile neutropenia is of particular concern in high-risk patients who have undergone stem cell transplant, according to William J. Hogan, MB, BCh, Assistant Professor of Medicine at the Mayo Clinic in Rochester, Minnesota. Dr. Hogan delivered an update on febrile neutropenia management in this...
Rolapitant for Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 2, 2015, rolapitant (Varubi) was approved for use in...
HPV-Positive Head and Neck Cancer: When Can Chemotherapy Be Omitted?
Are there patients with locally advanced squamous cell carcinoma of the head and neck associated with human papillomavirus (HPV) for whom chemotherapy can be omitted? Experts debated this question at the 2015 Debates and Didactics in Hematology and Oncology Conference in Sea Island, Georgia,...
Fred R. Hirsch, MD, PhD, Presented With 2015 Addario Lectureship Award
The Bonnie J. Addario Lung Cancer Foundation (ALCF) honored Fred R. Hirsch, MD, PhD, with the 2015 Addario Lectureship Award for his continued leadership and expertise in lung cancer treatment and research. Dr. Hirsch, CEO of the International Association for the Study of Lung Cancer (IASLC),...
Mantle Cell Lymphoma: Is Transplantation Still Necessary?
Autologous stem cell transplantation has played a critical role in the treatment of mantle cell lymphoma, but in the age of novel treatments, is it always warranted? Two experts in the field explored the question at the 2015 Debates and Didactics in Hematology and Oncology Conference sponsored by...
About the Summit
The research summit was part of the ASCO Obesity Initiative, which sought to increase awareness of the links between obesity and cancer and to foster research in this area that evaluated the impact of weight loss and increased activity on cancer outcomes. There have been hundreds of observational...
ASCO Statement Addresses Recommendations for Obesity Clinical Trials in Cancer Survivors
As reported in the Journal of Clinical Oncology by Jennifer A. Ligibel, MD, of Dana-Farber Cancer Institute, and colleagues, ASCO has issued a statement providing recommendations for obesity clinical trials in cancer survivors.1 ASCO convened the Research Summit on Advancing Obesity Clinical...
Dr. Cohen’s Approach to Managing Double-hit Lymphoma
All patients with aggressive non Hodgkin lymphoma should be evaluated for MYC and BCL2/6 gene expression, if possible, by fluorescent in situ hybridization and immunohistochemistry. Several intensive treatment regimens are available. Dr. Cohen favors dose-adjusted R-EPOCH for patients with...
Double-Hit Lymphoma: Many Treatment Strategies, No Standard of Care
"Double-hit lymphoma” represents a challenging malignancy without a standard-of-care treatment, although outcomes for some patients are better than was once believed, according to Jonathon B. Cohen, MD, Assistant Professor of Hematology and Medical Oncology at Emory University, Atlanta. Dr. Cohen...
Making Their Voices Heard: 118 Oncologists Speak Out About Stemming the High Cost of Cancer Drugs
In a bold move to shed light on the ramifications of the ever-increasing cost of cancer drugs for patients with cancer and for the health-care system, 118 prominent oncologists came together to write a commentary in Mayo Clinic Proceedings detailing their concerns.1 To learn more about these...
Our Children’s Future Is Our Responsibility
Cancer prevention is a child-care issue. With many of cancer’s instigators planting their seeds during childhood, we—as a profession and as a nation—must seize this important window of opportunity to protect the health and well-being of future generations. Current estimates suggest that up to...
Expert Point of View: Glenwood Goss, MD, FRCPC, FCPSA
Glenwood Goss, MD, FRCPC, FCPSA, Professor of Medicine and Director of Clinical and Translational Research at the Ottawa Hospital Cancer Centre and University of Ottawa, Canada, formally discussed the findings. He noted that this combination in advanced melanoma showed “limited progression-free...
First-Line Nivolumab/Ipilimumab Combination in Non–Small Cell Lung Cancer Shown to Be Tolerable
For advanced non–small cell lung cancer (NSCLC), first-line treatment with combined immune checkpoint blockade—in novel doses and schedules—was associated with deep and durable responses, encouraging progression-free survival, and much better tolerability than has been previously observed with...
Over Three-Quarters of People With Cancer Worldwide Have No Access to Safe Surgery
Over 80% of the 15 million people diagnosed with cancer worldwide in 2015 will need surgery, but less than one-quarter of them will have access to proper, safe, affordable surgical care when they need it, according to a major new Commission examining the state of global cancer surgery. The...
Cancer Incidence and Mortality Rates Worldwide
As discussed in the new series “Global Oncology Burden”, analysis of the cancer burden based on the regions as divided by the World Health Organization (WHO) (ie, Africa, the Americas, South-East Asia, Europe, Eastern Mediterranean, and Western Pacific), reveals the marked differences (see Table...
Thomas A. Stamey, MD, Noted Urologist and Prostate Cancer Expert, Dies at 87
Thomas A. Stamey, MD, Professor Emeritus of Urology at the Stanford University School of Medicine and a leader in the study and treatment of prostate cancer, died of Alzheimer’s disease September 4. He was 87. A True Pioneer in the Field Dr. Stamey helped lay the groundwork for the...
Decreased Mortality in Men With Unfavorable-Risk Prostate Cancer and Moderate or Severe Comorbidities Treated With Radiotherapy Alone
Men with unfavorable-risk prostate cancer and moderate or severe comorbidities had significantly decreased overall and cardiac mortality when treated with radiotherapy alone vs radiotherapy and androgen-deprivation therapy, according to a study described in a research letter in The Journal of the...
